Cargando…
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
Medulloblastoma is the most common malignant brain tumor of childhood, and represents a significant clinical challenge in pediatric oncology, since overall survival currently remains under 70%. Patients with tumors overexpressing MYC or harboring a MYC oncogene amplification have an extremely poor p...
Autores principales: | Henssen, Anton, Thor, Theresa, Odersky, Andrea, Heukamp, Lukas, El-Hindy, Nicolai, Beckers, Anneleen, Speleman, Frank, Althoff, Kristina, Schäfers, Simon, Schramm, Alexander, Sure, Ulrich, Fleischhack, Gudrun, Eggert, Angelika, Schulte, Johannes H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875771/ https://www.ncbi.nlm.nih.gov/pubmed/24231268 |
Ejemplares similares
-
RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
por: Gottlieb, Aline, et al.
Publicado: (2017) -
Targeting tachykinin receptors in neuroblastoma
por: Henssen, Anton G., et al.
Publicado: (2016) -
Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023) -
Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018) -
MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020)